Cite
MLA Citation
Shinji Takeuchi et al.. “Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer.” Cancer science, vol. 111, no. 2, 2020, pp. 561–570. http://access.bl.uk/ark:/81055/vdc_100099980444.0x000025